Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study

Charles W. Whitney; Virginia L. Brunetto; Richard J. Zaino; Samuel S. Lentz; Joel Sorosky; Deborah K. Armstrong; Roger B. Lee

doi:10.1016/j.ygyno.2003.09.018

Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study

Charles W. Whitney, Virginia L. Brunetto, Richard J. Zaino, Samuel S. Lentz, Joel Sorosky, Deborah K. Armstrong, Roger B. Lee

Research output: Contribution to journal › Article › peer-review

143 Scopus citations

Abstract

Objectives. The objectives of this study were to estimate the clinical response rate and toxicity of daily tamoxifen combined with intermittent weekly medroxyprogesterone acetate (MPA). Methods. This study reports the results of 61 patients with measurable advanced or recurrent endometrial carcinoma enrolled on this study to be treated with tamoxifen 40 mg p.o. daily plus alternating weekly cycles of MPA 200 mg p.o. daily. Results. One patient was excluded and two patients did not receive study treatment. The percent of patients responding (6 complete and 13 partial) was 33% (95% confidence interval [CI]: 21-46%) among 58 eligible patients who received therapy. Median progression-free survival (PFS) was 3 months and median overall survival (OS) was 13 months. Conclusion. The combination of daily tamoxifen and intermittent weekly medroxyprogesterone acetate is an active treatment for advanced or recurrent endometrial carcinoma. Further investigation of this combination is appropriate.

Original language	English (US)
Pages (from-to)	4-9
Number of pages	6
Journal	Gynecologic oncology
Volume	92
Issue number	1
DOIs	https://doi.org/10.1016/j.ygyno.2003.09.018
State	Published - Jan 2004
Externally published	Yes

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1016/j.ygyno.2003.09.018

Cite this

@article{b29564f9db9841f295b06259d7d4aaf2,

title = "Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study",

abstract = "Objectives. The objectives of this study were to estimate the clinical response rate and toxicity of daily tamoxifen combined with intermittent weekly medroxyprogesterone acetate (MPA). Methods. This study reports the results of 61 patients with measurable advanced or recurrent endometrial carcinoma enrolled on this study to be treated with tamoxifen 40 mg p.o. daily plus alternating weekly cycles of MPA 200 mg p.o. daily. Results. One patient was excluded and two patients did not receive study treatment. The percent of patients responding (6 complete and 13 partial) was 33% (95% confidence interval [CI]: 21-46%) among 58 eligible patients who received therapy. Median progression-free survival (PFS) was 3 months and median overall survival (OS) was 13 months. Conclusion. The combination of daily tamoxifen and intermittent weekly medroxyprogesterone acetate is an active treatment for advanced or recurrent endometrial carcinoma. Further investigation of this combination is appropriate.",

author = "Whitney, {Charles W.} and Brunetto, {Virginia L.} and Zaino, {Richard J.} and Lentz, {Samuel S.} and Joel Sorosky and Armstrong, {Deborah K.} and Lee, {Roger B.}",

note = "Funding Information: This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469) and the GOG Statistical and Data Center (CA 37517). The following member institutions participated in this study: ",

year = "2004",

month = jan,

doi = "10.1016/j.ygyno.2003.09.018",

language = "English (US)",

volume = "92",

pages = "4--9",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma

T2 - A Gynecologic Oncology Group study

AU - Whitney, Charles W.

AU - Brunetto, Virginia L.

AU - Zaino, Richard J.

AU - Lentz, Samuel S.

AU - Sorosky, Joel

AU - Armstrong, Deborah K.

AU - Lee, Roger B.

N1 - Funding Information: This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469) and the GOG Statistical and Data Center (CA 37517). The following member institutions participated in this study:

PY - 2004/1

Y1 - 2004/1

N2 - Objectives. The objectives of this study were to estimate the clinical response rate and toxicity of daily tamoxifen combined with intermittent weekly medroxyprogesterone acetate (MPA). Methods. This study reports the results of 61 patients with measurable advanced or recurrent endometrial carcinoma enrolled on this study to be treated with tamoxifen 40 mg p.o. daily plus alternating weekly cycles of MPA 200 mg p.o. daily. Results. One patient was excluded and two patients did not receive study treatment. The percent of patients responding (6 complete and 13 partial) was 33% (95% confidence interval [CI]: 21-46%) among 58 eligible patients who received therapy. Median progression-free survival (PFS) was 3 months and median overall survival (OS) was 13 months. Conclusion. The combination of daily tamoxifen and intermittent weekly medroxyprogesterone acetate is an active treatment for advanced or recurrent endometrial carcinoma. Further investigation of this combination is appropriate.

AB - Objectives. The objectives of this study were to estimate the clinical response rate and toxicity of daily tamoxifen combined with intermittent weekly medroxyprogesterone acetate (MPA). Methods. This study reports the results of 61 patients with measurable advanced or recurrent endometrial carcinoma enrolled on this study to be treated with tamoxifen 40 mg p.o. daily plus alternating weekly cycles of MPA 200 mg p.o. daily. Results. One patient was excluded and two patients did not receive study treatment. The percent of patients responding (6 complete and 13 partial) was 33% (95% confidence interval [CI]: 21-46%) among 58 eligible patients who received therapy. Median progression-free survival (PFS) was 3 months and median overall survival (OS) was 13 months. Conclusion. The combination of daily tamoxifen and intermittent weekly medroxyprogesterone acetate is an active treatment for advanced or recurrent endometrial carcinoma. Further investigation of this combination is appropriate.

UR - http://www.scopus.com/inward/record.url?scp=0742324890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742324890&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2003.09.018

DO - 10.1016/j.ygyno.2003.09.018

M3 - Article

C2 - 14751130

AN - SCOPUS:0742324890

SN - 0090-8258

VL - 92

SP - 4

EP - 9

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 1

ER -

Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this